Australia Relaxes Psychedelic-Assisted Therapy Rules, Sparking Safety Debate Among Clinicians
核心洞察
Australia's TGA has relaxed requirements for psychedelic-assisted therapy using MDMA and psilocybin, allowing non-psychologist support workers to be present and psychiatrists to leave after dosing.
Clinical psychologist Shai Hipperson warns the changes could endanger vulnerable trauma patients, citing the lack of standardized training benchmarks for facilitators.
The Australian Association of Psychologists (搜索) (AAPi) states the new rules exclude approximately 70% of psychologists from providing psychedelic-assisted therapy.
Australia's Therapeutic Goods Administration (搜索) (TGA) has relaxed the regulatory requirements governing psychedelic-assisted therapy, a move that has ignited sharp debate between advocates seeking improved patient access and clinicians warning of potential risks to vulnerable individuals.
The revised guidance, which took effect following a nine-month consultation process, modifies the framework established in 2023 when Australia became the first country to permit the use of MDMA for post-traumatic stress disorder (搜索) (PTSD) and psilocybin for treatment-resistant depression (搜索) within clinical settings.
Under the previous rules, both a psychiatrist and a clinical psychologist were required to remain present for the duration of a patient's psychedelic session, which can last up to eight hours. The new regulations eliminate the requirement for a clinical psychologist, allowing the second attending professional to be any support worker registered with the Psychology Board, Medical Board, Nurse and Midwifery Board — with mental health experience — or the Occupational Therapy Board. Additionally, psychiatrists or doctors may now leave the clinic after the drug has been administered.
Clinical concerns over patient safety
Clinical psychologist Shai Hipperson, founder of the Gold Coast-based Conscious Mind Centre, has been administering both MDMA and psilocybin in therapy sessions for just over a year. She expressed serious reservations about the regulatory changes.
"We've had several patients have really difficult times," Hipperson said. "They really had a hard time and it lasted for a period of time, and that distress for people can be a lot under the medicine. If the facilitators are feeling anxious or overwhelmed because of what's happening with the patient, they're directly feeding off that and it can exacerbate and make it worse."
Hipperson emphasized that there is currently no standardized benchmark for training, leaving patients uncertain whether their therapists have completed a two-day or a two-year training course. "While these skills can be taught, there's so much more foundational knowledge that go underneath to really make a huge difference for this, both in delivery and patient outcomes," she noted.
She also raised concerns about a new requirement that clinics be within a 15-minute drive of a health facility with an emergency department. While intended to enhance safety, Hipperson argued this could paradoxically reduce access for regional and rural Australians. "When we look at metropolitan centres, hospitals are located in very distinct regions which means we're now going to have clinics in concentrated parts of metropolitan cities or in very large towns. But our regional and rural towns are still missing out. So, access is not expanding but maybe being more concentrated."
Professional bodies voice opposition
The Australian Association of Psychologists (搜索) (AAPi) has also strongly criticized the changes. AAPi Executive Director Tegan Carrison stated that the new framework would prevent approximately 70 percent of psychologists from conducting psychedelic-assisted therapy.
"The TGA has ignored years of expert feedback and chosen to maintain an arbitrary two-tier system that excludes most psychologists from providing psychedelic-assisted therapy," Carrison said. "This decision is profoundly concerning, both professionally and from a patient safety perspective."
Carrison argued that the broadening of who can administer therapy sessions to those with specific endorsements fails to include the "overwhelming majority of registered psychologists" in Australia. "It sends a message that endorsement status matters more than competence and experience. That precedent has implications well beyond psychedelic-assisted therapy and risks further diminishing the standing of the broader psychology workforce."
The AAPi maintains that competence in psychedelic-assisted therapy is obtained through post-registration education and supervision, and that decisions about participation should be based on competence rather than assumptions tied to a particular endorsement.
Patient perspectives and therapeutic potential
Despite the controversy, patients who have undergone the treatment describe transformative outcomes. Duncan Livingston, who suffered from a complex combination of PTSD and depression (搜索) for more than four decades stemming from childhood abuse, underwent three sessions — two with MDMA and one with psilocybin.
"MDMA allowed me to go back into past memories, including the traumatic memories, but they weren't traumatic to deal with," Livingston said. "It was like reliving the experiences, both good and bad, from life. But being there as somewhat of an observer rather than being completely in there and being re-traumatised again. That allowed talk therapy to work for the first time in 40 years."
Livingston described his psilocybin session as a psychedelic, spiritual experience that "broke the cycle" of his depression (搜索). "What this treatment has done for me has nearly let me be reborn again in some ways. It's brought some joy back into my life. It's beautiful," he said.
Hipperson cautioned that the therapy is not a panacea. "These medicines don't take away what's happened to you, and some people have endured some horrific things in life. These medicines bring those things to the surface. They're not a one magic bullet, one-size-fits-all approach — it is very hard work. But it can be very rewarding for patients to go through this journey."
Mechanisms of action
MDMA is used for PTSD patients because it numbs the amygdala — the brain region responsible for emotional reaction — allowing individuals to confront past traumas without shutting down emotionally. Psilocybin, used for depression (搜索), enables the brain to create new neural pathways. "What the psilocybin actually does is it reconnects all of the brain networks all at the same time and it almost scatters the signal around the brain," Hipperson explained. "So that ruminating or looping thought of struggling with your self-worth or your identity or who you are basically goes away under the psilocybin condition."
Regulatory context
To qualify for the treatment, patients must have been prescribed at least two different antidepressants and undergone another type of therapy without showing progress. A psychiatrist then determines whether the patient is capable of undergoing therapy in a heightened emotional state. The TGA has stated that the new guidance is now in place but has not evaluated the drugs' quality, efficacy, or safety, and the treatments remain unapproved and not suitable for most Australians.
Clinical psychologist Monica Schweickle offered a measured perspective: "It's a promising sign that things are moving slowly and carefully and mindfully in the right direction to increase access. But I also think we can't forego safety in the sake of making something cheaper."